AndreaLora(Lora)KosslerMDFACS

Oculo-Plastic & Orbital Reconstructive Surgery

Associate Professor of Ophthalmology Director, Oculofacial Plastic & Reconstructive Surgery Co-Director, Multidisciplinary Thyroid Eye Disease Center Co-Director, Orbital and Ocular Oncology Center

Join to view full profile

Dr. Kossler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kossler's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Summary

Andrea Lora Kossler, MD, is Associate Professor of Ophthalmology at Stanford University School of Medicine and Director of the Ophthalmic Plastic, Reconstructive Surgery and Orbital Oncology Service. She specializes orbital reconstructive and aesthetic facial plastic surgery. Dr. Kossler’s research interests include thyroid eye disease and orbital oncology.

Education & Training

University of Miami Hospital and ClinicsFellowship, Ophthalmic Plastic and Reconstructive Surgery, 2010 - 2012
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2007 - 2010
Mount Sinai Medical Center of FloridaInternship, Internal Medicine, 2006 - 2007
Georgetown University School of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2012 - 2025
FL State Medical License 2010 - 2014
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Annual AAO Conference: Best Ocular & Orbital Oncology Paper AAO- American Academy of Ophthalmology
Marvin Quickert Thesis Award ASOPRS- American Society of Ophthalmic Plastic & Reconstructive Surgery
Valedictorian & Summa Cum Laude Georgetown University School of Medicine

Clinical Trials

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Start of enrollment: 2021 Sep 16
Active, not recruiting
Phase 4
A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED) Start of enrollment: 2021 Dec 03
Active, not recruiting
Phase 3
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Start of enrollment: 2022 Jul 01
Active, not recruiting
Phase 2, Phase 3

Publications & Presentations

PubMed

6 citations
Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
Tiffany C Ho, Robi N Maamari, Andrea L Kossler, Connie M Sears, Suzanne K Freitag
Ophthalmic Plastic and Reconstructive Surgery. 2022-09-09
15 citations
Stimulating Tear Production: Spotlight on Neurostimulation.
Michael D Yu, Ji Kwan Park, Andrea L. Kossler
Clinical Ophthalmology. 2021-10-20
29 citations
Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy.
Connie Martin Sears, Amee D. Azad, Chrysoula Dosiou, Andrea L. Kossler
Ophthalmic Plastic and Reconstructive Surgery. 2021-05-01